Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.3SBio has acquired worldwide rights of Pegsiticase for all indications from EnzymeRx for a total consideration of $6.25m.
Subscribe to our email newsletter
3SBio plans to develop pegsiticase in China and will seek partnerships for development outside of China.
Pegsiticase (Uricase-PEG 20) is a pegylated recombinant uricase derived from Candida utilis, modified by the attachment of multiple 20 kilodalton molecules of polyethylene glycol (PEG), and is being developed for the treatment of refractory gout and tumor lysis syndrome.
EnzymeRx president and CEO Tony Fiorino said that this drug has the potential to be a best-in-class agent with strong efficacy and what has been a very clean safety profile to date.
3SBio director and CEO Jing Lou said that they look forward to developing this innovative biological medicine and making it available to gout patients worldwide.